# Three Records on One Axis, Set Against Each Other

> Ipamorelin vs CJC-1295 vs Tesamorelin - Growth Hormone Axis Research Peptides — A side-by-side reading of three Growth Hormone Axis research peptides - ipamorelin, the CJC-1295 pairing and tesamorelin - across receptor, endpoint, sample size, duration, reversibility and regulatory standing.

**SIDE BY SIDE / EVIDENCE LADDER**

Same physiological target, three completely different evidence bases. What follows compares the studies, not the marketing.

## The short version

All three entries on this page do the same thing in the body: they make the pituitary release more of its own growth hormone, instead of supplying growth hormone directly. [Ipamorelin](/ipamorelin) uses one receptor, [tesamorelin](/tesamorelin) uses a different one, and the [CJC-1295 pairing](/cjc1295-ipamorelin) uses both at once.

Where they separate is not mechanism but evidence. Tesamorelin has been through randomized trials lasting a year, with scans measuring the fat it was supposed to shift, and the results have been pooled across five studies [8]. Ipamorelin has one human trial, which did not show what it set out to show [3]. The pairing has no human trial at all.

So the useful comparison is not which one is strongest. It is which claims about each one are actually backed by a study, and which are backed only by a receptor diagram. The table below lines that up row by row.

## The comparison matrix

| Dimension | Ipamorelin | CJC-1295 / Ipamorelin | Tesamorelin (Egrifta) |
| --- | --- | --- | --- |
| Receptor | GHS-R1a (ghrelin receptor) | GHRH-R plus GHS-R1a | GHRH-R |
| Second messenger | Calcium, via Gq | Cyclic AMP via Gs, plus calcium via Gq | Cyclic AMP, via Gs |
| Highest-tier human evidence | one Phase 2 RCT, primary endpoint missed, n=114 [3] | none - the combination has never been trialed | five RCTs, pooled in a meta-analysis [8] |
| Best-measured endpoint | time to first tolerated meal, 25.3 h vs 32.6 h, p=0.15 [3] | GH and IGF-1 kinetics of the CJC-1295 half alone [10] | visceral adipose tissue, mean difference -27.71 cm2 [8] |
| Human exposure studied | up to 7 days, intravenous [3] | not studied as a pair | 26 weeks [14] and 52 weeks [16] |
| Human pharmacokinetics | yes - terminal half-life about 2 h, IV, n=8 per dose level [4] | CJC-1295 with DAC only: GH raised 2- to 10-fold for 6 days or more [10] | approved-product schedule; overnight GH +0.5 micrograms per liter over 2 weeks [15] |
| What reverses on stopping | not characterized in humans | not characterized | visceral fat reaccumulates [16] |
| Regulatory status | not approved anywhere; research chemical | not approved anywhere; research chemicals | FDA-approved 2010, HIV lipodystrophy only [13] |
| Leading caution | class-level cardiac finding for a related GHS-R1a agonist in rats [2] | untested as a blend; mismatched half-lives [10][11] | benefit is contingent on continued dosing [16] |

## Receptor and mechanism

The axis has two doors into the same room. GHRH analogues such as tesamorelin bind the growth-hormone-releasing-hormone receptor, a class-B G-protein-coupled receptor, and raise cyclic AMP through Gs. Growth-hormone-releasing peptides such as ipamorelin bind GHS-R1a, the ghrelin receptor, and raise intracellular calcium through Gq. Both sit on the same pituitary somatotroph and both end in a growth-hormone pulse.

That two-door architecture is the entire justification for the pairing, and it is not merely theoretical: co-activating the cloned growth-hormone-secretagogue receptor and the GHRH receptor in transfected HeLa cells produced a cyclic AMP response roughly twice that of GHRH-receptor activation alone [12].

Ipamorelin adds a further wrinkle worth stating precisely, because it is the compound's whole reputation. It releases growth hormone without raising ACTH or cortisol above the level GHRH itself produces, even at doses more than 200-fold above its growth-hormone ED50 in rats and swine [6]. That is a genuine selectivity advantage over older GHRPs, and it is a mechanistic property, not an outcome.

## Evidence maturity - the row that matters most

If a reader takes one row from the table, take this one.

Tesamorelin's evidence is mature by any ordinary standard: five randomized controlled trials pooled into a 2026 meta-analysis, reporting -27.71 cm2 in visceral adipose tissue, -4.28% in hepatic fat fraction and +1.42 kg in lean body mass, all at P<0.001 and without serious adverse events [8]. Beneath the pooled figure sit a six-month JAMA trial in 50 participants with two imaging endpoints [14] and a 52-week program in 410 randomized participants that also captured what happens after the drug is withdrawn [16].

Ipamorelin's evidence is immature in humans and rich in animals. One Phase 2 trial, 114 participants, primary endpoint missed at p=0.15 [3]; one pharmacokinetic study in healthy men [4]; and beyond that, rats, swine, ferrets and cell preparations [1][5][6].

The pairing's evidence does not exist as such. Its components are documented - CJC-1295 with DAC raising growth hormone two- to ten-fold for six days or more in healthy adults [10], and the albumin bioconjugation that makes that possible measured in rats [11] - but no controlled trial has ever evaluated the two peptides together for any outcome.

## What each was actually studied for

Indication drift is the most common error in reading this literature, so it is worth being blunt about what each compound's trials were about.

Ipamorelin's Phase 2 trial was a gastrointestinal study. It tested a ghrelin-receptor agonist in postoperative ileus - the sluggish gut that follows bowel surgery - and its endpoint was how soon a patient tolerated a meal [3]. It was never a body-composition trial, an anti-aging trial or a sleep trial.

Tesamorelin's trials were body-composition studies in a specific clinical population: HIV-positive adults on antiretroviral therapy with lipodystrophy, with visceral adipose tissue and hepatic fat as endpoints [14][16]. The one healthy-volunteer study measured hormonal response and glucose handling over two weeks [15].

The pairing has no studied indication because it has no study. The claims attached to it - recovery, sleep, body composition - come from community report and from mechanism, not from an endpoint anyone pre-specified.

## Study design, side by side

Set the three designs next to one another and the asymmetry becomes hard to miss.

**Route.** Ipamorelin's human data are intravenous - twice-daily bolus in the trial [3], fifteen-minute infusions in the pharmacokinetic study [4]. Tesamorelin's are daily subcutaneous injection at 2 mg [14][15][16]. The subcutaneous route that dominates non-clinical use of ipamorelin and the CJC-1295 pairing has never been characterized in a published human study.

**Duration.** Seven days at most for ipamorelin [3]. Twenty-six and fifty-two weeks for tesamorelin [14][16]. A one-week exposure and a one-year exposure answer different questions, and neither substitutes for the other.

**Endpoint type.** Ipamorelin's was a clinical time-to-event measure [3]. Tesamorelin's were imaging measures - cross-sectional visceral fat area and hepatic lipid fraction - which are objective and quantitative, and which is why its effect size is stated in square centimeters rather than in impressions [8][14].

**Control and follow-up.** Both human programs were placebo-controlled. Only tesamorelin's captured what happens after treatment stops, and it found reaccumulation [16] - a finding that no amount of mechanism could have predicted with confidence.

## Regulatory standing

Tesamorelin is an approved prescription medicine in the United States, under NDA 022505 since November 2010, for excess abdominal fat in HIV-infected adults with lipodystrophy [13]. Nothing beyond that indication is approved.

Ipamorelin and CJC-1295 are not approved anywhere and are supplied as research chemicals. Both moved through the FDA's interim Section 503A bulk-substances process and out of it again: added to Category 2 in September 2023, removed in September 2024 after the nominators withdrew, with Pharmacy Compounding Advisory Committee review following.

All three are prohibited in sport at all times under WADA category S2, and the unapproved pair may additionally fall under S0 as non-approved substances. Detection methods for growth hormone secretagogues are established at accredited laboratories.

## The caution that matters most for each

For **ipamorelin**, the leading caution is a class signal from a molecule that is not ipamorelin. A 28-day integrated preclinical safety study of the GHS-R1a agonist GSK894281 found dose-dependent myocardial degeneration and necrosis in rats, with elevated serum heart-type fatty-acid-binding protein at the highest doses and no rise in cardiac troponin [2]. No comparable long-duration cardiovascular study of ipamorelin exists in any species, which is why the signal remains open rather than resolved.

For the **CJC-1295 pairing**, the leading caution is structural. Pairing a multi-day albumin-bound agent [10][11] with one cleared in hours produces an exposure profile that no study has characterized, and continuous GHRH-pathway drive is not the pulsatile stimulus the synergy literature examined.

For **tesamorelin**, the leading caution is that the benefit is rented rather than owned: visceral fat reaccumulates upon discontinuation [16]. Alongside that sits the class-wide point that stimulating the axis raises IGF-1, a growth factor, with limited long-term oncologic-safety data and active malignancy as a labeled contraindication.

Across all three, the constant is a metabolic one: a review of growth-hormone secretagogues as a class identified increased blood glucose from decreased insulin sensitivity as the chief safety concern, and concluded that long-term cancer-incidence and mortality data are still needed [9].

---

An independent digest of the growth-hormone-axis literature that reports sample sizes, endpoints and effect sizes exactly as published - not a clinic, not a supplier, and not a source of dosing advice.